SUPERPARAMAGNETIC IRON-OXIDE - CLINICAL TIME-RESPONSE STUDY

被引：25

作者：

GANDON, Y

HEAUTOT, JF

BRUNET, F

GUYADER, D

DEUGNIER, Y

CARSIN, M

机构：

[1] Département d'Imagerie Médicale Hôpital Pontchaillou, Rennes

[2] Service de Médecine Interne et Hépatologie, Hôpital Pontchaillou, Rennes

来源：

EUROPEAN JOURNAL OF RADIOLOGY | 1991年 / 12卷 / 03期

关键词：

MAGNETIC RESONANCE IMAGING; RETICULOENDOTHELIAL SYSTEM; CONTRAST MEDIUM; TIME RESPONSE STUDY; MRI;

D O I：

10.1016/0720-048X(91)90072-4

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Superparamagnetic iron oxide (AMI 25) is a promising new contrast agent for imaging the reticuloendothelial-system. Iron oxide crystals possess a large magnetic susceptibility and enhance proton relaxation rates, especially transverse relaxation (T2). In order to guide the clinical utilization of this contrast media we analyzed 4 patients with malignant lesions of the liver before and after slow intravenous administration (20-mu-mol Fe/kg) of AMI 25. We performed two magnetic resonance (MR) sequences at different times using a 0.35 T magnet. MR signal-to-noise ratio (SNR) of the reticuloendothelial system (particularly the liver SNR) decrease promptly. The maximum decrease in SNR (67-72% for the liver, 46-65% for the spleen, 23-41% for the bone marrow) is observed 3 h after injection (P < 0.01). However, except the peak of contrast enhancement in T1-weighted sequences of splenic tissue, the curve describes a plateau within 30 min and 6 h, allowing a delay between injection and imaging. T2-weighted sequences give a greater contrast-to-noise ratio (CNR) by adding the spontaneous tumor contrast to the effect yielded by AMI 25. These results suggest that images must be acquired between 1 and 6 h after intravenous administration of superparamagnetic iron oxide.

引用

页码：195 / 200

页数：6

共 18 条

[1]

Alderson, Adams, McNeil, Et al., Computed tomography, ultrasound and scintigraphy of the liver in patients with colon or breast carcinoma: a prospective comparison, Radiology, 149, pp. 225-230, (1983)

[2]

Freeny, Marks, Ryan, Bolen, Colorectal carcinoma evaluation with CT: prospective staging and detection of postoperative recurrence, Radiology, 158, pp. 347-353, (1986)

[3]

Stark, Wittenberg, Butch, Ferrucci, Hepatic metastases: a randomized controlled, comparison of detection with MR and CT, Radiology, 165, pp. 399-406, (1987)

[4]

Saini, Stark, Hahn, Wittenberg, Brady, Ferrucci, Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system, Radiology, 162, pp. 211-216, (1987)

[5]

Saini, Stark, Hahn, Bousquet, Introcasso, Wittenberg, Brady, Ferrucci, Ferrite particles: superparamagnetic MR contrast agent for enhanced detection of liver carcinoma, Radiology, 162, pp. 217-222, (1987)

[6]

Stark, Weissleder, Elizondo, Et al., Superparamagnetic iron oxide: Clinical application as a contrast agent for MR imaging of the liver, Radiology, 168, pp. 297-301, (1988)

[7]

Weissleder, Hahn, Stark, Et al., Superparamagnetic iron oxide: enhanced detection of focal splenic tumors with MR imaging, Radiology, 169, pp. 399-403, (1987)

[8]

Weissleder, Elizondo, Stark, Et al., The diagnosis of splenic lymphoma by MR imaging: value of superparamagnetic iron oxide, AJR, 152, pp. 175-180, (1989)

[9]

Bacon, Stark, Park, Et al., Ferrite particles: a new magnetic resonance imaging contrast agent, lack of acute or chronic hepatotoxicity after intravenous administration, J Lab Clin Med, 110, pp. 164-171, (1987)

[10]

Weissleder, Stark, Engelstad, Et al., Superparamagnetic iron oxide: pharmacokinetics and toxicity, AJR, 152, pp. 167-173, (1989)

← 1 2 →